109 related articles for article (PubMed ID: 19237805)
1. Use of iron sucrose in dialysis patients sensitive to iron dextran.
Haddad A; Abbadi R; Marji A
Saudi J Kidney Dis Transpl; 2009 Mar; 20(2):208-11. PubMed ID: 19237805
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial.
Van Wyck DB; Cavallo G; Spinowitz BS; Adhikarla R; Gagnon S; Charytan C; Levin N
Am J Kidney Dis; 2000 Jul; 36(1):88-97. PubMed ID: 10873877
[TBL] [Abstract][Full Text] [Related]
3. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?
Sav T; Tokgoz B; Sipahioglu MH; Deveci M; Sari I; Oymak O; Utas C
Ren Fail; 2007; 29(4):423-6. PubMed ID: 17497463
[TBL] [Abstract][Full Text] [Related]
4. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients.
Fishbane S; Lynn RI
Clin Nephrol; 1995 Oct; 44(4):238-40. PubMed ID: 8575123
[TBL] [Abstract][Full Text] [Related]
6. [Parenteral iron therapy: problems and possible solutions].
Hoigné R; Breymann C; Künzi UP; Brunner F
Schweiz Med Wochenschr; 1998 Apr; 128(14):528-35. PubMed ID: 9592894
[TBL] [Abstract][Full Text] [Related]
7. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
8. Safety profiles of total dose infusion of low-molecular-weight iron dextran and high-dose iron sucrose in renal patients.
Atalay H; Solak Y; Acar K; Govec N; Turk S
Hemodial Int; 2011 Jul; 15(3):374-8. PubMed ID: 21564503
[TBL] [Abstract][Full Text] [Related]
9. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
[TBL] [Abstract][Full Text] [Related]
10. Comparison of parenteral iron sucrose and ferric chloride during erythropoietin therapy of haemodialysis patients.
Wu CJ; Lin HC; Lee KF; Chuang CK; Chen YC; Chen HH
Nephrology (Carlton); 2010 Feb; 15(1):42-7. PubMed ID: 20377770
[TBL] [Abstract][Full Text] [Related]
11. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
[TBL] [Abstract][Full Text] [Related]
12. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
[TBL] [Abstract][Full Text] [Related]
13. Iron dextran treatment in peritoneal dialysis patients on erythropoietin.
Suh H; Wadhwa NK
Adv Perit Dial; 1992; 8():464-6. PubMed ID: 1361849
[TBL] [Abstract][Full Text] [Related]
14. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients.
Cavdar C; Temiz A; Yeniçerioğlu Y; Calişkan S; Celik A; Sifil A; Onvural B; Camsari T
Scand J Urol Nephrol; 2003; 37(1):77-82. PubMed ID: 12745750
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy.
Ayub R; Tariq N; Adil MM; Iqbal M; Junaid A; Jaferry T
J Coll Physicians Surg Pak; 2008 Jul; 18(7):424-7. PubMed ID: 18760066
[TBL] [Abstract][Full Text] [Related]
16. A trial of two iron-dextran infusion regimens in chronic hemodialysis patients.
Agarwal R; Davis JL; Hamburger RJ
Clin Nephrol; 2000 Aug; 54(2):105-11. PubMed ID: 10968685
[TBL] [Abstract][Full Text] [Related]
17. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
Chen YC; Hung SC; Tarng DC
Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
[TBL] [Abstract][Full Text] [Related]
18. 12-week clinical effects of erythropoietin espogen in end stage renal patients undergoing hemodialysis.
Thitiarchakul S; Tasanarong A
J Med Assoc Thai; 2007 Apr; 90(4):636-42. PubMed ID: 17487116
[TBL] [Abstract][Full Text] [Related]
19. Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
Tagboto S; Cropper L; Mostafa S; Turner J; Bailey G; Pugh-Clarke K
J Ren Care; 2008 Sep; 34(3):112-5. PubMed ID: 18786076
[TBL] [Abstract][Full Text] [Related]
20. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels.
Maruyama Y; Nakayama M; Yoshimura K; Nakano H; Yamamoto H; Yokoyama K; Lindholm B
Nephrol Dial Transplant; 2007 May; 22(5):1407-12. PubMed ID: 17264097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
